Pfizer (PFE) closed at $29.21, up 2.96% on the day, outperforming the S&P 500. However, the company faces headwinds with projected Q3 EPS declining 17.24% year-over-year and full-year earnings expected to drop 8.39%. The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 9.63, trading at a discount to industry averages. Earnings are scheduled for November 3, 2026.

Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities.

Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027.

The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

Bristol Myers Squibb (BMY) has outperformed the S&P 500 with a 35.8% gain over the past year, driven by strong performance from its Growth Portfolio including Opdivo Qvantig, Reblozyl, Camzyos, and Breyanzi. Recent FDA approvals like Zenbexus and positive pipeline progress offer long-term growth potential. However, the legacy portfolio faces continued generic competition, and much of the near-term optimism appears reflected in current valuations. Analysts recommend a cautious stance with a Hold rating.

Pfizer's stock has moved above its 50-day moving average, supported by new drug launches and acquisitions. While the company faces significant headwinds from declining COVID-19 product sales and an upcoming patent cliff, its diversified portfolio, strong oncology pipeline, obesity drug berobenatide program, attractive 6.1% dividend yield, and $9.7 billion in cost savings through 2029 provide support. Analysts recommend holding the stock at current levels given its inexpensive valuation relative to peers.

The article explains how to identify stocks with positive earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) filter, which compares the most recent analyst estimates against consensus estimates. The strategy combining positive ESP with Zacks Rank #3 or better has historically resulted in 70% positive earnings surprises and 28.3% average annual returns. Johnson & Johnson and Pfizer are highlighted as medical stocks with positive ESPs ahead of their upcoming earnings reports.

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

Zacks Research Daily features analysis of 16 major stocks including JPMorgan Chase, ASML, and Chevron, plus two microcap stocks. JPMorgan benefits from strong earnings and diversified revenues; ASML faces balanced opportunities and risks from AI demand; Chevron shows strong production growth and cash flow. Additional coverage includes Pfizer, Valero Energy, and Constellation Energy, with mixed outlooks across sectors.

The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories.

Roche received FDA approval for Tecentriq in combination with chemotherapy for adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer. The phase III ATOMIC study demonstrated a 50% reduction in recurrence or death risk, with 86% disease-free survival at 36 months versus 76% for chemotherapy alone. This marks Tecentriq's 12th U.S. indication and positions it as the first approved adjuvant immunotherapy for this cancer type.

Pfizer has been heavily searched on Zacks.com lately. The stock returned +0.6% over the past month, underperforming the S&P 500's +1.3% gain. Pfizer holds a Zacks Rank #2 (Buy) rating based on earnings estimate revisions and other factors. The company is expected to report declining earnings year-over-year but has consistently beaten consensus estimates in recent quarters. Pfizer trades at a valuation discount to peers with a B grade on the Value Style Score.